Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.44 – $2.68
Volume15,459
Market cap$112M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$111.63M
Price / earnings
—
Price / book
11.59×
Price / sales
1.87×
EV / sales
2.04×
EV / EBITDA
-50.1×
Profitability
Earnings per share
-$0.20
Return on assets
-13.68%
Return on equity
-87.58%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.7×
Current ratio
4.95×
Quick ratio
3.85×
Cash ratio
2.37×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for APYX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$14.03M
$13.88M
$12.49M
$19.16M
$12.88M
$11.37M
$9.43M
$14.22M
Cost of revenue
$5.03M
$5.01M
$4.57M
$7.17M
$4.58M
$4.29M
$3.77M
$5.26M
Gross profit
$9M
$8.87M
$7.93M
$12M
$8.3M
$7.08M
$5.67M
$8.96M
Selling, general and administrative
$8.72M
$9.88M
$8.07M
$11.04M
$8.33M
$8.83M
$7.91M
$10.9M
Research and development
$849K
$793K
$765K
$944K
$801K
$824K
$804K
$1.12M
Total operating expenses
$9.56M
$10.67M
$8.8M
$11.99M
$9.05M
$9.66M
$8.72M
$12.01M
Operating income
-$562K
-$1.8M
-$875K
$11K
-$756K
-$2.57M
-$3.05M
-$3.05M
Interest expense
-$1.41M
-$1.39M
-$1.37M
-$1.41M
-$1.41M
-$1.39M
-$1.38M
-$1.65M
Income before taxes
-$1.69M
-$2.95M
-$2M
-$1.15M
-$1.88M
-$3.69M
-$4.12M
-$4.57M
Income taxes
$116K
$124K
$143K
$94K
$78K
$49K
$49K
$89K
Net income
-$1.81M
-$3.07M
-$2.14M
-$1.24M
-$1.96M
-$3.74M
-$4.17M
-$4.66M
Net income attributable to common shareholders
-$1.79M
-$3.24M
-$2.11M
-$1.3M
-$1.98M
-$3.78M
-$4.15M
-$4.63M
EBITDA
-$375K
-$1.61M
-$673K
$232K
-$592K
-$2.44M
-$2.91M
-$2.91M
Basic earnings per share
-$0.04
-$0.07
-$0.05
-$0.03
-$0.05
-$0.09
-$0.10
-$0.12
Diluted earnings per share
-$0.04
-$0.07
-$0.05
-$0.03
-$0.05
-$0.09
-$0.10
-$0.12
Recent news
Company coverage with links to the original publishers.
Apyx Medical announced publication of clinical data demonstrating that a combination treatment approach using Avéli® for subcision and Renuvion® for plasma radiofrequency energy shows significant improvement in cellulite and skin laxity. In a study of 22 patients, 81.8% showed improvement in cellulite appearance at 180 days post-treatment, with objective imaging confirming measurable reductions in dimple volume and histological evidence of increased collagen and elastin.
Apyx Medical received FDA 510(k) clearance to add power liposuction capability to its AYON Body Contouring System, an advanced liposuction modality using reciprocating cannulas to improve surgical efficiency. The company plans a limited commercial launch to work with early adopters before broader scaling. This expansion positions AYON as a comprehensive all-in-one platform combining fat removal, tissue contouring, and electrosurgical capabilities.
Apyx Medical Corporation has priced a public offering of 2,762,431 shares of common stock at $3.62 per share, expecting to raise approximately $10 million for working capital and general corporate purposes.
Apyx Medical Corporation received FDA clearance for its AYON Body Contouring System, which combines multiple technologies for body contouring procedures. The company plans to launch the system with key surgeons in the second half of 2025.
Apyx Medical Corporation has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, which is designed to provide comprehensive body contouring solutions through an all-in-one platform.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.